We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. The company's purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various ... Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. The company's purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. Show more
REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S...
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe...
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar...
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed...
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in...
REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines...
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million...
In Wednesday’s pre-market trading, U.S. index futures were trading sideways, reflecting investors’ caution after a positive session, with focus turning to the upcoming Federal Reserve...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.26 | 1.8387553041 | 14.14 | 14.76 | 14 | 172505 | 14.3862534 | CS |
4 | 2.27 | 18.713932399 | 12.13 | 14.76 | 11.19 | 260187 | 13.09424359 | CS |
12 | -1 | -6.49350649351 | 15.4 | 18 | 11.0101 | 278409 | 14.78749455 | CS |
26 | 5.67 | 64.9484536082 | 8.73 | 18 | 8.39 | 221510 | 14.25989616 | CS |
52 | 4.55 | 46.192893401 | 9.85 | 18 | 6.7 | 144774 | 12.93065548 | CS |
156 | 4.9 | 51.5789473684 | 9.5 | 18 | 5.2 | 116030 | 12.03414741 | CS |
260 | 4.9 | 51.5789473684 | 9.5 | 18 | 5.2 | 116030 | 12.03414741 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions